Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 1;17(1):38.
doi: 10.1186/s13045-024-01560-7.

Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma

Esther Wei Yin Chang  1   2 , Ya Hwee Tan  3   4 , Jason Yongsheng Chan  5   6   7
Affiliations
Review

Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma

Esther Wei Yin Chang et al. J Hematol Oncol. .

Abstract

Peripheral T cell lymphoma (PTCL) represents a group of heterogeneous hematological malignancies, which are notoriously challenging to treat and outcomes are typically poor. Over the past two decades, clinical prognostic indices for patient risk stratification have evolved, while several targeted agents are now available to complement combination chemotherapy in the frontline setting or as a salvage strategy. With further understanding of the molecular pathobiology of PTCL, several innovative approaches incorporating immunomodulatory agents, epigenetic therapies, oncogenic kinase inhibitors and immunotherapeutics have come to the forefront. In this review, we provide a comprehensive overview of the progress in developing clinical prognostic indices for PTCL and describe the broad therapeutic landscape, emphasizing novel targetable pathways that have entered early phase clinical studies.

Keywords: AITL; Epigenetics; Immunotherapy; Precision Oncology; Prognosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Regulatory approved agents for R/R PTCL
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Vose J, Armitage J, Weisenburger D, International T-C. Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–30. doi: 10.1200/JCO.2008.16.4558. - DOI - PubMed
    1. Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66(6):443–59. doi: 10.3322/caac.21357. - DOI - PubMed
    1. Smith A, Crouch S, Lax S, Li J, Painter D, Howell D, Patmore R, Jack A, Roman E. Lymphoma incidence, survival and prevalence 2004–2014: sub-type analyses from the UK’s Haematological Malignancy Research Network. Br J Cancer. 2015;112(9):1575–84. doi: 10.1038/bjc.2015.94. - DOI - PMC - PubMed
    1. Liu S, Liu W, Li H, Yang L, Song Y, Zhang X, Cheng Y, Li Q, Li H, Wang N, Zhu J, Ji J. Epidemiological characteristics of peripheral T-Cell lymphoma: a Population-based study. Front Oncol. 2022;12:863269. doi: 10.3389/fonc.2022.863269. - DOI - PMC - PubMed
    1. Muto R, Miyoshi H, Sato K, Furuta T, Muta H, Kawamoto K, Yanagida E, Yamada K, Ohshima K. Epidemiology and secular trends of malignant lymphoma in Japan: analysis of 9426 cases according to the World Health Organization classification. Cancer Med. 2018;7(11):5843–58. doi: 10.1002/cam4.1805. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources